Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Lowers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Myriad Genetics Reports Fiscal Third-Quarter 2015 Financial Results
May 5, 2015 4:05 PM EDTTotal Revenue of $180.0 Million Adjusted Diluted EPS of $0.40 and Diluted EPS of $0.29 myRisk Hereditary Cancer Panel Ended Third Quarter at 58 Percent Conversion Myriad Acquires MVZ Clinic to Facilitate Reimbursement in Germany Company Provides Fiscal Fourth-Quarter 2015 Financial Guidance
SALT LAKE CITY, May 5, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN) today announced financial results for its fiscal third-quarter and nine months ended March 31, 2015, provided an update on recent business highlights and provided fiscal fourth-quarter... More
